I'm really disappointed that you have preemptively cutoff our members from asking questions. It really is unprecedented.

I'd like to call at least for a second hearing for this nominee.

For those who have a preexisting condition, I vote no. The PRESIDING OFFICER. Debate is not in order during a vote.

I come to the floor of the Senate tonight with my colleagues to share the stories of families in our home States whose lives are now healthier or have even been saved because of the Affordable Care Act, including those who depend on…

today I wish to recognize an exceptional public servant, Dr. Beth Bell, who is retiring from the directorship of the National Center for Emerging and Zoonotic Infectious Diseases, NCEZID, at the Centers for Disease Control and Prevention…

I thank my colleague. Madam President, I thank my colleagues from the west coast for the amazing job of pointing out the egregious nature of this poison pill amendment that was added to this very critical bill. We are here tonight after…

today I wish to recognize U.S. Army CPT Lewis Larkin O'Hern III for his extraordinary dedication to duty and honorable service to our Nation. During his exemplary career with the Army from May 2008 to January 2017, Captain O'Hern made an…

I would like to express my heartfelt thanks to all of our colleagues in the House and the Senate who worked so hard to make this bill the best it could be for the patients and families we serve. In particular, I want to express my…

--and it is a pleasure to say that. Some may know him as ``the guy in the aviators'' deboarding Air Force Two or the man in the 1967 Corvette in the viral Internet video, gleeful, as he had the rare opportunity to drive himself around in…

I wish to start by expressing my appreciation to all of my colleagues who have worked so hard on the priorities in the 21st Century Cures bill, including investing in tackling our hardest to treat diseases, confronting the opioid epidemic…

I ask unanimous consent that Megan Howard, a fellow with Senator Murray's HELP Committee staff, be granted floor privileges for the remainder of the 114th Congress. The PRESIDING OFFICER. Without objection, it is so ordered.

I ask unanimous consent that the Senate proceed to executive session and the Banking Committee be discharged from further consideration of PN1053, the nomination of John Mark McWatters, of Texas, to be a Member of the Board of Directors of…

I come to the floor this afternoon to join my colleagues who have already noted that we are now at an unbelievable, unprecedented 195 days--over 6 months--since the President nominated Judge Merrick Garland to the Supreme Court. Do you…

How do companies distinguish between consumer complaints and adverse event reports, and do you believe that most companies report adverse events to the FDA?

I am glad that, in the absence of stricter Federal laws, the individual States like my home State of Washington have taken steps to restrict or reduce the use of certain ingredients.

The cosmetics portion of the law has barely been touched since it passed in 1938.

I am really pleased that we are holding this hearing to talk about products that millions of consumers and families use each day.

Congress has spent a great deal of time modernizing nearly every aspect of the Food, Drug and Cosmetic Act.

FDA has no authority to review or confirm the safety of the ingredients in fragrances used in cosmetics before they enter the market.

I really commend their work to bring together so many stakeholders from the business and consumer community to develop the Personal Care Product Safety Act.

In spite of that explosive growth putting millions of products on the market, the FDA's authority has not changed.

I'm concerned that our regulatory system currently can't provide that assurance.

I'm excited about the President's Precision Medicine Initiative and the Vice President's Cancer Moonshot which can help ensure that the next generation of treatments and cures are developed right here in the United States.

very concerned that this oversight currently proposed could impede patient access to existing high-quality or state-of-the-art tests and threaten needed innovation.

But that promise cannot be realized unless doctors and patients have the assurance that when a test result demonstrates risk of a disease, provides an early diagnosis, or suggests a treatment, that result is correct and reliable.